Aclaris Therapeutics
ACRS
57 hedge funds and large institutions have $65M invested in Aclaris Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 10 closing their positions.
6,800% more call options, than puts
Call options by funds: $69K | Put options by funds: $1K
41% more capital invested
Capital invested by funds: $46.1M → $65M (+$18.8M)
8% less funds holding
Funds holding: 62 → 57 (-5)
8.16% less ownership
Funds ownership: 67.97% → 59.82% (-8.2%)
45% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 22
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$1.53M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$967K |
| 3 |
JGC
J. Goldman & Co
New York
|
+$887K |
| 4 |
Renaissance Technologies
New York
|
+$344K |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$325K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MFN Partners
Boston,
Massachusetts
|
-$5.41M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.02M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$662K |
| 4 |
TI
Telemetry Investments
New York
|
-$462K |
| 5 |
Jane Street
New York
|
-$386K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$9.03K | -4,035 | -92% |
|
52
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $1K | – | – | – |
|
53
Millennium Management
New York
| $724 | -$231K | -103,137 | -27% |
|
|
MP
54
MFN Partners
Boston,
Massachusetts
| – | -$5.41M | -3,338,718 | Closed |
|
|
OMC
55
Old Mission Capital
Chicago,
Illinois
| – | -$154K | -94,800 | Closed |
|
56
Man Group
London,
United Kingdom
| – | -$151K | -93,518 | Closed |
|
|
PP
57
Paloma Partners
Greenwich,
Connecticut
| – | -$116K | -71,800 | Closed |
|
58
Verition Fund Management
Greenwich,
Connecticut
| – | -$105K | -65,000 | Closed |
|
|
VF
59
Virtu Financial
New York
| – | -$61K | -37,447 | Closed |
|
|
AG
60
Aperio Group
Sausalito,
California
| – | -$35K | -21,062 | Closed |
|
61
BNP Paribas Financial Markets
Paris,
France
| – | -$17.3K | -10,655 | Closed |
|
62
Barclays
London,
United Kingdom
| – | -$18.5K | -8,276 | -100% |
|
63
Bank of America
Charlotte,
North Carolina
| – | -$9.72K | -4,344 | -99% |
|
|
PCM
64
Prelude Capital Management
New York
| – | -$1K | -375 | Closed |
|
ACRS Hedge Fund Activity: Q3 2020 in Review
57 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2020, worth a combined $65M — up 41% from $46.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ACRS and 5 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 12 added.
The largest buyer was Foresite Capital Management III, opening a new position worth an estimated $1.53M. The largest seller was MFN Partners, exiting entirely with an estimated $5.41M sold.
- 57 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2020, down from 62 in Q2 2020.
- Funds reported $65M of Aclaris Therapeutics stock for Q3 2020, up 41% quarter-over-quarter.
- 5 funds opened new Aclaris Therapeutics positions in Q3 2020 and 10 closed out, a net change of -5 holders.
- The largest Aclaris Therapeutics buyer in Q3 2020 was Foresite Capital Management III, an estimated $1.53M added.
- The largest Aclaris Therapeutics seller in Q3 2020 was MFN Partners, an estimated $5.41M sold.
Based on aggregated 13F filings for Q3 2020.